PT-141: research overview

The short version

PT-141, generically known as bremelanotide, is a synthetic cyclic heptapeptide that activates melanocortin receptors in the brain — specifically MC4R and MC3R — concentrated in the hypothalamus and limbic system. Unlike vascular-acting compounds that work peripherally on blood vessels, it works centrally on the neural circuitry of sexual motivation.

The FDA approved it in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ^[22]. That is the full scope of its approval. Use in men, in postmenopausal women, or to boost sexual performance in people without a clinical diagnosis is not approved and has not been evaluated in large controlled trials with a pre-specified primary endpoint.

Two phase-3 RCTs (RECONNECT, n=1,267 premenopausal women with HSDD) demonstrated statistically significant improvements in sexual desire and desire-related distress ^[20]. Nausea affected approximately 40% of users in the long-term safety study ^[21] — the most prominently documented adverse effect.

A frank note on scope: this page covers a sexual-health topic plainly. Real-world reports, both benefits and adverse effects, are included in labeled-anecdotal form because that is what the evidence framework for this desk calls for.

What it is

PT-141 is a synthetic cyclic heptapeptide lactam analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Its full structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge between the aspartic acid and lysine side chains. It is structurally related to melanotan II but is not the same compound: melanotan II is a non-selective agonist at melanocortin receptors 1 through 5, while PT-141/bremelanotide is more selective for MC3R and MC4R and lacks the C-terminal amide of melanotan II. The two should not be conflated and are not interchangeable.

PT-141 is administered by subcutaneous injection. It is not orally bioavailable in established form.

How it works

PT-141 activates central melanocortin receptors — primarily MC4R, expressed densely in the hypothalamic medial preoptic area and related limbic circuits — that are involved in sexual desire and arousal. By engaging MC4R, it is thought to modulate dopaminergic pathways governing sexual motivation, producing a desire-focused effect that originates in the brain rather than in peripheral vascular tissue.

A 2022 fMRI study (n=31 premenopausal women with HSDD) provided mechanistic neuroimaging evidence: MC4R agonism significantly increased sexual desire for up to 24 hours and altered brain processing of erotic stimuli, including enhanced amygdala-insula functional connectivity and cerebellar/supplementary-motor activity ^[19].

An important nuance: a 2025 animal study in female Syrian hamsters found that bremelanotide did not enhance the rewarding aspect of sexual interaction (conditioned place preference) and did not change melanocortin-receptor mRNA in the mesolimbic dopamine system ^[18]. This suggests its mechanism is more specific to desire circuitry than to the reward system more broadly — but animal-to-human translation in this domain is inherently limited.

MC4R is also expressed in appetite circuits, which is why high-frequency research dosing has been associated with reduced food intake and body weight. This is a pharmacological off-target consideration, not an approved or recommended use.

What the research shows

Phase-3 efficacy (RECONNECT trials, n=1,267): Two identical, double-blind, placebo-controlled RCTs found bremelanotide 1.75 mg subcutaneous as-needed improved both coprimary endpoints over 24 weeks: integrated FSFI desire score +0.35 (P<0.001) and integrated FSDS-DAO item-13 distress score −0.33 (P<0.001) versus placebo ^[20]. The most common adverse events were nausea, flushing, and headache.

Long-term safety extension (RECONNECT open-label, n=684, 52 weeks): Sexual-desire improvements were sustained over the extension period; no new safety signals emerged. Drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[21].

Regulatory label details (FDA-approved US prescribing information): Approved indication is HSDD in premenopausal women; approved dose is 1.75 mg subcutaneous as needed (maximum one dose per 24 hours, no more than 8 doses per month); terminal half-life approximately 2.7 hours; a warning covers transient blood-pressure increase ^[22].

Mechanistic neuroimaging: The 2022 fMRI study (n=31 women with HSDD) demonstrated increased brain processing of sexual stimuli after MC4R agonism, supporting the central mechanism ^[19].

Critical perspectives: Published re-analyses have argued the observed effects on desire and distress, while statistically significant, are small in absolute magnitude and question the clinical meaningfulness of the endpoints chosen. These critiques do not overturn the phase-3 results but are part of the honest literature.

Preclinical nuance: The 2025 hamster study found no enhancement of sexual reward via the mesolimbic dopamine pathway ^[18] — a finding that complicates simple characterizations of the mechanism.

Reported effects, cautions, and safety

What research-use communities report (anecdotal, not clinical evidence): The dominant reported benefit is a felt increase in sexual desire — described as originating mentally rather than physically, as a return of wanting rather than simply a physical response. People describe arousal building without direct stimulation, heightened sensitivity to touch, and some report effects persisting well into the following day. A distinct subset of men (off-label, non-approved use) report spontaneous erections driven by desire rather than mechanical stimulation. Some users also describe greater emotional closeness during intimacy. A real and recurring report is that the compound did nothing at all — non-response appears highly individual. The long window of effect (effects can start hours after dosing and persist overnight) is reported both as a feature by some and as a timing complication by others.

Documented adverse effects (from approved clinical data): Nausea is the most common adverse effect, affecting approximately 40% of long-term users and described as the leading cause of discontinuation in some accounts ^[21]. Flushing and warmth (20.6%), headache (12.0%), and injection-site irritation are also well-documented from the clinical trials ^[21]. Transient blood-pressure increase is documented; the FDA label warns against use by people with uncontrolled hypertension or known cardiovascular disease ^[22]. Skin, gum, and mucous-membrane darkening (hyperpigmentation) is reported with repeated frequent dosing, attributed to MC1R activation by the compound; some darkening may not fully reverse after stopping ^[22].

Unapproved uses: Any use outside the approved indication (premenopausal women with HSDD) is off-label. This includes all use in men and all use in postmenopausal women.

Research-chemical supply caution: Material sold outside the pharmaceutical approval framework as a 'research chemical' has no regulatory quality verification. Unregulated melanocortin-peptide products circulate, and forensic evidence of mislabeled or contaminated material has been documented in the broader category. This adds supply-chain risk on top of the compound's own documented effects.

No dose recommendation is given on this page. Doses appearing above are reported as published study parameters attributed to their trials.

Where it fits on this desk

PT-141 is the narrowest-indication FDA approval on this desk. Its phase-3 evidence is real and its mechanism is well characterized for the approved indication. The gap between 'approved for premenopausal women with HSDD' and 'widely used as a general sexual enhancer' is large and not filled by controlled evidence. This desk covers it in the approved context, reports the community anecdotes plainly, and documents the side-effect profile without minimizing it.